{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:41:27Z","timestamp":1795178487434,"version":"4.10.3"},"reference-count":23,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2023YC27"],"award-info":[{"award-number":["2023YC27"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2024,6,8]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate the efficacy and safety of vonoprazan and tetracycline (VT) dual therapy as first-line treatment for\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection in patients with penicillin allergy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomised controlled trial, treatment-na\u00efve adults with\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection and penicillin allergy were randomised 1:1 to receive either open-label VT dual therapy (vonoprazan 20 mg two times per day+tetracycline 500 mg three times a day) or bismuth quadruple therapy (BQT; lansoprazole 30 mg two times per day+colloidal bismuth 150 mg three times a day+tetracycline 500 mg three times a day+metronidazole 400 mg three times a day) for 14 days. The primary outcome was non-inferiority in eradication rates in the VT dual group compared with the BQT group. Secondary outcomes included assessing adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>300 patients were randomised. The eradication rates in the VT group and the BQT group were: 92.0% (138\/150, 95% CI 86.1% to 95.6%) and 89.3% (134\/150, 95% CI 83.0% to 93.6%) in intention-to-treat analysis (difference 2.7%; 95% CI \u22124.6% to 10.0%; non-inferiority p=0.000); 94.5% (138\/146, 95% CI 89.1% to 97.4%) and 93.1% (134\/144, 95% CI 87.3% to 96.4%) in modi\ufb01ed intention-to-treat analysis (difference 1.5%; 95% CI \u22124.9% to 8.0%; non-inferiority p=0.001); 95.1% (135\/142, 95% CI 89.7% to 97.8%) and 97.7% (128\/131, 95% CI 92.9% to 99.4%) in per-protocol analysis (difference 2.6%; 95% CI \u22122.9% to 8.3%; non-inferiority p=0.000). The treatment-emergent adverse events (TEAEs) were significantly lower in the VT group (14.0% vs 48.0%, p=0.000), with fewer treatment discontinuations due to TEAEs (2.0% vs 8.7%, p=0.010).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      VT dual therapy demonstrated efficacy and safety as a first-line treatment for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection in the penicillin-allergic population, with comparable efficacy and a lower incidence of TEAEs compared with traditional BQT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR2300074693.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2024-332640","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T13:20:27Z","timestamp":1718976027000},"page":"1414-1420","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":53,"title":["Simplified\n                    <i>Helicobacter pylori<\/i>\n                    therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy"],"prefix":"10.1136","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3549-6846","authenticated-orcid":false,"given":"Wen","family":"Gao","sequence":"first","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Liu","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Li","sequence":"additional","affiliation":[{"name":"Tsinghua University School of Medicine, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"TCM and Integrative Medicine Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ye","sequence":"additional","affiliation":[{"name":"TCM and Integrative Medicine Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Dong","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"Liu","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-4752","authenticated-orcid":false,"given":"Guigen","family":"Teng","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Tian","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9885-261X","authenticated-orcid":false,"given":"Jinpei","family":"Dong","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyi","family":"Ge","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[{"name":"GI Department, Peking University First Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"2025090715120432000_73.9.1414.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"2025090715120432000_73.9.1414.2","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12692","article-title":"PPI-amoxicillin dual therapy for helicobacter pylori infection: an update based on a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2020","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.3","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12918","article-title":"Eradication rate and safety of a \"simplified rescue therapy\": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of helicobacter pylori infection previously failed in eradication: a real-world, retrospective clinical study in China","volume":"27","author":"Gao","year":"2022","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.4","first-page":"5027","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of helicobacter pylori strains in China","volume":"11","author":"Zhong","year":"2021","journal-title":"Am J Cancer Res"},{"key":"2025090715120432000_73.9.1414.5","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12947","article-title":"A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies","volume":"28","author":"Gao","year":"2023","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.6","first-page":"2171","article-title":"Family history of gastric cancer and helicobacter pylori treatment","volume":"382","author":"Kim","year":"2020","journal-title":"N Engl J Med"},{"key":"2025090715120432000_73.9.1414.7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025090715120432000_73.9.1414.8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.14309\/ajg.0000000000002298","article-title":"It is time for a paradigm shift in design, execution, and publishing of comparative helicobacter pylori treatment trials","volume":"118","author":"Graham","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025090715120432000_73.9.1414.9","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13039","article-title":"Vonoprazan and amoxicillin dual therapy as the first-line treatment of helicobacter pylori infection: a systematic review and meta-analysis","volume":"29","author":"Du","year":"2024","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.10","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.14309\/ajg.0000000000002255","article-title":"Hybrid, high-dose dual and bismuth quadruple therapies for first-line treatment of helicobacter pylori infection in Taiwan: a multicenter, open-label","volume":"118","author":"Hsu","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025090715120432000_73.9.1414.11","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.1059321","article-title":"Differences in beta-lactam and penicillin allergy: beyond the West and focusing on Asia-Pacific","volume":"3","author":"Mak","year":"2022","journal-title":"Front Allergy"},{"key":"2025090715120432000_73.9.1414.12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2302\/kjm.51.supplement2_33","article-title":"Gastric spirochaetes: 100 years of discovery before and after kobayashi","volume":"51 Suppl 2","author":"Marshall","year":"2002","journal-title":"Keio J Med"},{"key":"2025090715120432000_73.9.1414.13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2036.1994.tb00285.x","article-title":"Short report: omeprazole-tetracycline combinations are inadequate as therapy for helicobacter pylori infection","volume":"8","author":"Al-Assi","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090715120432000_73.9.1414.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2012.08.021"},{"key":"2025090715120432000_73.9.1414.15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00535-023-01991-y","article-title":"Minocycline vs. tetracycline in bismuth-containing quadruple therapy for helicobacter pylori rescue treatment: a multicentre, randomized controlled trial","volume":"58","author":"Huang","year":"2023","journal-title":"J Gastroenterol"},{"key":"2025090715120432000_73.9.1414.16","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","article-title":"Retrospective analysis CONFIRMS tetracycline quadruple as best helicobacter pylori regimen in the USA","volume":"64","author":"Alsamman","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2025090715120432000_73.9.1414.17","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12570","article-title":"Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of helicobacter pylori","volume":"24","author":"Nyssen","year":"2019","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.18","doi-asserted-by":"publisher","DOI":"10.1111\/all.13168"},{"key":"2025090715120432000_73.9.1414.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.05.055"},{"key":"2025090715120432000_73.9.1414.20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10620-023-07886-5","article-title":"Why the vonoprazan helicobacter pylori therapies in the US-European trial produced unacceptable cure rates","volume":"68","author":"Graham","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2025090715120432000_73.9.1414.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309197"},{"key":"2025090715120432000_73.9.1414.22","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12880","article-title":"Effects of enhanced education for patients with the helicobacter pylori infection: a systematic review and meta-analysis","volume":"27","author":"Zha","year":"2022","journal-title":"Helicobacter"},{"key":"2025090715120432000_73.9.1414.23","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12040737","article-title":"Treatment of helicobacter pylori infection in patients with penicillin allergy","volume":"12","author":"Liu","year":"2023","journal-title":"Antibiotics (Basel)"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-332640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:12:13Z","timestamp":1757283133000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-332640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,8,8]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/gutjnl-2024-332640"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-332640","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}